>-Internexin (INA) has been proposed to be a surrogate marker for the 1p/19q codeletion in oligodendroglial tumors (OTs). We analyzed INA expression in 83 glioma and 21 oligodendroglial phenotype-mimicking tumors (OMT) to assess its usefulness in differential diagnosis and its correlation with 1p/19q status; in particular, INA expression in gliomas with isolated/partial 1p or 19q deletions was assessed. >-Internexin expression and 1p/19q codeletion were present in 92% (34/37) of codeleted tumors (p G 0.0001). By contrast, INA was found in only 20% of cases with isolated/partial 1p aberrations and 36% of cases without 1p/19q deletions; it was also found in 63% (10/16) of cases with isolated/partial 19q aberrations. >-Internexin expression was more specific in high-grade than in lowgrade gliomas (66% vs 31%). Notably, a subset of tumors (10/83) displayed a biphasic INA expression pattern that was significantly associated with proliferation rate, whereas all areas harbored the 1p/19q codeletion. Only no or weak INA expression was seen in OMTs. In summary, INA is a useful marker to differentiate OTs from astrocytic tumors and OMTs, but INA expression is not exclusively linked to OTs harboring the 1p/19q codeletion. Moreover, it can sometimes be heterogeneously distributed within tumors, which emphasizes the need for 1p/19q analysis by molecular genetic techniques for diagnosis.
INTRODUCTION
In World Health Organization (WHO) grade II to IV gliomas, the distinction between astrocytoma (A), oligodendroglioma (O), and mixed oligoastrocytoma (OA) has critical impact on prognostic evaluation and treatment considerations but can be difficult because of the somewhat subjective histopathologic criteria (1) . Analysis of molecular markers, specifically loss of heterozygosity on chromosomes 1p and 19q (LOH 1p/19q), has considerably reduced diagnostic uncertainties because 1p/19q codeletions frequently occur in O and OA and correlate with favorable outcome scores (2Y5). To date, however, the molecular/genetic effects of LOH 1p/19q have not been fully determined, and the clinical impact of isolated or partial deletions of 1p or 19q remains poorly defined.
A recent study suggests that >-internexin (INA), an intermediate neurofilament that has been associated with developmental, degenerative, and inflammatory processes of the central nervous system (CNS), is a surrogate marker for the combined 1p/19q deletion in WHO grade II to IV glioma (6) . However, whether INA expression correlates with isolated and/or partial deletions on 1p and 19q has not been clarified. This study was conducted to evaluate INA expression in WHO grade II to IV oligodendroglial and astrocytic gliomas and to determine the extent to which it correlates with 1p/19q codeletions and isolated and/or partial deletions on chromosomes 1p and 19q. In addition, we analyzed INA expression in CNS tumors that can mimic oligodendrogliomas to assess its role for the differential diagnosis of these challenging tumors.
MATERIALS AND METHODS

Tumor Samples
We studied 83 untreated gliomas, including A, OA, O, glioblastoma without oligodendroglial component (GBM), and glioblastoma with oligodendroglial component (GBMO) and 21 oligodendroglial phenotype-mimicking tumors (OMTs); the latter group included dysembryoplastic neuroepithelial tumor (DNT), central neurocytoma (CNC), clear cell ependymoma (CCE), pilocytic astrocytoma (PA), and metastasis of renal cell cancer (MRCC). The cases had been collected between 2006 and 2009 at the Center for Neuropathology and Prion Research at the Ludwig Maximilians-University Munich, Germany. An overview of the cases is provided in Tables 1 and 2 . The study protocol was reviewed and approved by the institutional review board of the Ludwig-Maximilians-University, Munich, Germany (AZ 216/14).
2-Hm paraffin sections was visualized using hematoxylin and eosin staining. For immunohistochemistry (IHC), sections were subjected to standardized staining on a benchmark staining machine with a 3,3 ¶-diaminobenzidine detection system according to the manufacturer's instructions (Ventana Medical Systems, Tucson, AZ). Antibodies used were antiYhuman glial fibrillary acidic protein (monoclonal mouse, clone 6F2; Dako, Glostrup, Denmark) and antiYmicrotubule-associated protein 2 (clone HM-2; Sigma, St. Louis, MO), and mouse antiY>-internexin monoclonal antibody (clone 2E3; Invitrogen, Darmstadt, Germany). The histologic diagnosis was made according to the 2007 WHO classification of tumors of the CNS (1). >-Internexin expression was evaluated by 2 observers semiquantitatively as described previously (6) and scored as negative (no staining), weakly positive (G10% stained cells), or strongly positive (910% stained cells). This classification is based on the overall percentage of tumor cells independent of their distribution within the tumor.
In cases of a biphasic INA expression pattern, proliferative activity in the respective areas was determined using anti-human Ki67 antibody (mouse monoclonal, clone MIB-1; Dako). For quantification of Ki67-positive cells, INA strong and weak or negative areas were selected in the anti-INAY stained sections and the corresponding areas were identified in consecutive Ki67-stained sections. For all cases, representative pictures of the Ki67 labeling from both an area with strong INA staining and an area with weak/negative staining (400Â magnification; area, 35,525 Km 2 for each) were taken with a BX50 Olympus microscope (Olympus Deutschland GmbH, Hamburg, Germany). Cell count was performed using Cell D Software (Olympus Deutschland GmbH) according to the manufacturer's instructions; 236 T 14 cells were counted per representative high-power field.
Polymerase Chain Reaction Amplification of Microsatellite Markers
Loss of heterozygosity on the short arm of chromosome 1 (1p) and on the long arm of chromosome 19 (19q) was detected using 5 tetranucleotide markers for each chromosomal region (D1S1608, D1S548, D1S1592, D1S1184, and D1S1161 for chromosome 1p; D19S433, D19S431, D19S718, D19S559, and D19S601 for chromosome 19q), as previously described (7, 8) . The distribution of the markers throughout the entire chromosomal arms also allowed the detection of partial deletions (Table 3) . Special care was taken to avoid cross-contamination. To this end, the samples of each patient were analyzed in separate experimental rounds including a no template control for each microsatellite primer pair.
Microsatellite Analysis
Polymerase chain reaction products were analyzed on highly resolving Spreadex gels using the Elchrom submerged gel electrophoresis system (both from Elchrom Scientific, Cham, Switzerland) and subsequently visualized by SYBR Gold. For LOH analysis, allele signal intensity of the tumor sample was compared with the corresponding allele band of the blood control sample taken from the same patient. Loss of heterozygosity was diagnosed when at least 3 of 5 tetranucleotide markers per chromosome were informative showing a clear signal loss as determined by 2 independent observers. Partial deletions were diagnosed when at least 1 marker showed a clear signal loss and at least 1 other did not.
Statistics
Graphs and statistics were done with Excel (Microsoft, Redmond, WA), SigmaPlot, and SigmaStat (Systat Software GmbH, Erkrath, Germany). The correlation between INA expression and 1p/19q status was assessed by the Fisher exact probability test (www.graphpad.com/quickcalcs/contingency1. cfm). Continuously scaled variables (e.g. Ki67 labeling index) were analyzed with the Mann-Whitney rank sum test. p G 0.05 was considered significant. All data are expressed as mean T SEM.
RESULTS
Histologic classification, 1p/19q status, and INA expression of the 83 glioma cases examined are summarized in Table 1 , and the 21 OMT cases are summarized in Table 2 . . Biphasic tumors were defined as those that had areas with strong INA staining and had sharp borders with areas with weak/negative staining, that is, at least a 5-fold difference in labeling ratio. These distinct patterns could be identified easily at both low and high magnifications ( Fig. 1 ). 
INA Expression Within WHO Grade II to IV Gliomas
Correlation of INA Expression and Histology
Each row shows an individual tumor; the corresponding columns show the status of the respective microsatellite markers on 1p and 19q arranged in the same order as on the chromosomal arms relative to the centromere region (C).
Latin (Fig. 3) . The overall positive predictive value (PPV) of INA expression (weak and strong) for the 1p/19q codeletion was 63%, the negative predictive value (NPV) was 90%, sensitivity (SEN) was 92%, and specificity (SPEC) was 57%. The corresponding values for strong INA expression were PPV 82%, NPV 75%, SEN 62%, and SPEC 89%, respectively.
The respective values for strong INA expression within the subpopulation of gliomas harboring an oligodendroglial phenotype (including GBMO) were PPV 85%, NPV 65%, SEN 73%, and SPEC 79%. The specificity of INA expression for detecting a 1p/19q codeletion was higher in highgrade glioma (HGG, 67%) than in low-grade glioma (LGG, 31%). Also, the NPV increased from 67% in LGG to 96% HGG. The other parameters were PPV (LGG, 68%; HGG, 58%) and SEN (LGG, 90%; HGG, 94%). An association of INA expression and 1p/19q codeletion was also observed when the data were stratified according to histologic subgroups (Table 1) 
Correlation of Biphasic INA Expression Pattern and Intratumoral 1p/19q Status
Because INA expression has been proposed as a surrogate marker for LOH 1p/19q, it is of special interest to have identified several cases with a biphasic expression pattern of INA. We performed a separate LOH analysis of the differentially INA-expressing areas of biphasic tumors. The 2 tumors with the most prominent biphasic INA expression (strong positive, i.e. presumably 1p/19q codeleted areas vs negative areas, i.e. potentially without deletion) were analyzed. Interestingly, both INA-positive and -negative areas clearly harbored the 1p/19q codeletion (Fig. 4) .
Correlation of INA Expression and Ki67 Labeling Index
Within biphasic tumors, comparative analysis of Ki67 labeling revealed a significantly higher labeling index in INAhigh-expressing areas (n = 10; 8.4% T 1.9%) versus the areas with weak (n = 8; 1.4% T 0.4%) or no INA expression (n = 2; 1%) (Mann-Whitney test, p G 0.01; Fig. 2 ).
INA Expression in Tumors Mimicking an Oligodendroglial Phenotype
To investigate the usefulness of INA staining in the differential diagnosis of entities mimicking the histomorphology of oligodendroglial tumors, 15 primary brain tumors (4 DNT, 1 CCE, 4 CNC, and 6 PA) and 6 intracranial MRCC were examined for INA expression. Weak INA expression was found in 13% of primary brain tumors (1/4 CNC and 1/6 PA). Notably, none of these tumors exhibited strong INA staining. In MRCC, there was weak INA expression in 66.7% (4/6); again, no case displayed strong INA positivity. 1p/19q status was available for all of the PA, and none showed any loss of chromosomal material.
DISCUSSION
>-Internexin expression has recently been proposed as a surrogate marker for prognostic/predictive favorable 1p/19q codeletions in WHO grade II to IV glioma with oligodendroglial differentiation, but its relationship to isolated/partial deletions on chromosomes 1p or 19q has not been addressed (6) . The issue is of clinical relevance as the prognostic/ predictive value of partial deletions considerably differs from 1p/19q codeletions. Isolated/partial deletions of 1p are rare events predominantly found in astrocytoma and data regarding prognostic relevance remain controversial (4, 9Y15). In contrast, isolated deletions of 19q can be found in up to 19% of oligodendroglial tumors and may precede 1p deletions in them (4); however, they do not correlate with favorable outcome scores (4, 14Y16). Therefore, only 1p/19q codeletions are considered to be clinically relevant (5) . Thus, to determine the utility of INA IHC as surrogate marker for the favorable 1p/19q codeletion in routine diagnosis, it is important to characterize INA expression levels in cases with isolated/partial 1p or 19q deletions. Polymerase chain reactionYbased microsatellite analysis for 1p/19q LOH is well suited for routine clinical use and enables reliable and reproducible mapping of LOH on both chromosomes; the use of multiple microsatellite markers allows the determination of isolated/partial deletions at different sites on both chromosomes (Table 3) (8) . Moreover, this method allows differential analysis of small areas with different morphologic phenotypes within a single tumor (7) .
INA Expression in WHO Grade II to IV Gliomas
Histological examination of all 83 gliomas studied revealed that INA was highly associated with an oligodendroglial phenotype. Strong INA positivity was found only in 5.9% (2/34) of astroglial tumors. Interestingly, one of the latter groups presented with pure astrocytic morphology (A II) but harbored a 1p/19q codeletion. This case was diagnosed by stereotactic biopsy procedures, so it is possible that an oligodendroglial tumor component was missed. In contrast to the study of Ducray et al (6), who did not find any INA expression within WHO grade II astrocytomas, approximately two thirds of A II in the present study had at least weak INA expression. This finding, however, is in accordance with recently published data from a tissue microarray-based study (17) : in that study low INA expression (0%Y5% positive cells) was detected in 93.4% of astrocytoma and a medium/strong (5%Y25% or 925% positive cells) expression in 6.6% of cases; the respective values for oligodendroglial tumors were 45.8% and 54.2%.
Notably, a so-far-unknown subset of 10 cases had a biphasic INA expression pattern exhibiting distinct areas of strong expression alternating with areas if weak or no INA expression. This pattern was independent of differential astroglial versus oligodendroglial tumor components, which again indicates that INA expression is not exclusively related to oligodendroglial morphology but probably influenced by other unknown factors. Biphasic tumors were additionally assessed for possible relationships between INA expression and Ki67 labeling index. Quantitative analysis of proliferation activity detected a significantly higher number of Ki67-positive cells in areas of strong INA versus weak or no INA expression. At first view, this seems to contradict the fact that INA was found to be a prognostic marker associated with prolonged survival (6), whereas high Ki67 values generally are associated with higher tumor grade and worse prognosis (18) . However, in the study of Ducray et al (6) , the hazard ratio associated with INA expression was no longer significant when adjusted for 1p/19q codeletion. Thus, INA expression may provide a surrogate marker for the overall molecular effects of 1p/19q codeletion with respect to prognosis, whereas at the molecular level, INA itself may be associated with as-yet-undefined molecular/ genetic processes that accompany malignant tumorigenesis.
INA Expression Correlates With 1p/19q Status
In line with the study of Ducray et al, our data highlight a positive correlation between INA and favorable 1p/19q codeletion; 92% of codeleted tumors expressed INA. On the other hand, 36% of nondeleted tumors and 52% of tumors with isolated/partial deletions on chromosomes 1p or 19q had INA expression. Thus, the specificity of INA expression for 1p/19q codeletions was considerably lower (57%) versus the finding of 86% by Ducray et al. This, in turn, critically limits the utility of INA expression as a reliable surrogate marker for 1p/19q codeletions. A higher specificity (89%) could be achieved when only strong INA expression was considered, but this lowered the SEN to 62%. Moreover, biphasic intratumoral INA expression patterns (despite homogeneous 1p/19q status) indicated that INA expression is regulated by additional factors. In summary, INA expression was associated both with an oligodendroglial phenotype and with a 1p/19q deletion but not exclusively linked to the clinically relevant codeletion. Interestingly, a trend toward INA expression was also observed in cases with isolated/partial deletions of 19q, whereas cases with isolated/partial expression of 1p resembled cases without any deletion (Fig. 3) . Moreover, INA expression was more specific for the 1p/19q codeletion in HGG compared with LGG.
Biologic Relevance of INA Expression
The finding that INA may also be expressed in cases of isolated/partial deletions of 1p or 19q is important from a biologic point of view. The frequent loss of 1p/19q in oligodendroglial tumors suggests that these chromosomal arms carry as-yet-unidentified tumor suppressor genes, the absence of which is a key event in the pathogenesis of oligodendrogliomas. However, the deletion of tumor suppressor genes does not provide an explanation for the favorable clinical behavior in 1p/19q codeleted oligodendroglial tumors, indicating that other genes within the relatively large region of LOH on 1p and 19q are involved. This hypothesis is compatible with data on small interstitial deletions on 1p (11), which have been associated with worse clinical outcome instead of longer survival. Unfortunately, little is known about the functional role of INA and potential interacting signaling molecules in primary brain tumors. Some studies indicate functional roles for INA in neuronal differentiation (19, 20) , neurite outgrowth (21) , and axonal transport processes (22) . Therefore, INA has been introduced as a marker for developing and mature neurons during neurogenesis. Expression of INA in oligodendroglial tumors might thus originate from bipotential precursor cells capable of differentiating in both neurons and oligodendrocytes. Indeed, this fate has been described for Olig-2Ypositive precursor cells in the ventral ventricular zone of the spinal cord (23) . Furthermore, Olig-2 expression seems to be more intense and uniform in highgrade oligodendroglial tumors (24) . Analogous results were found in our study regarding INA, that is, the expression showed a higher specificity in HGG versus LGG. Furthermore, it was accompanied by a higher proliferation activity in all 10 biphasic tumors analyzed. These observations fit well with the model of tumor cells frequently reexpressing earlier developmental markers on dedifferentiation.
INA Expression in OMT
We also investigated the applicability of INA IHC in the differential diagnosis of tumors mimicking an oligodendroglial phenotype. Although primary brain tumors only occasionally showed weak INA staining, renal cell carcinoma metastases frequently exhibited weak INA expression. This is consistent with previous studies reporting coexpression of neuronal intermediate filaments in nonneuronal tumors (25) . In contrast to oligodendroglial tumors, no OMT case displayed strong INA expression. Thus, strong INA expression would militate against the diagnosis of an OMT.
Taken together, our data confirm a strong association between the 1p/19q codeletion characteristic for oligodendroglial tumors, and INA, especially in cases of strong INA expression or high-grade tumors. Therefore, INA is a useful marker in the differential diagnosis of oligodendroglial versus astrocytic tumors. This is of particular interest in small stereotactic biopsy specimens in which the typical ''honeycomb'' pattern of oligodendroglial tumors is often less obvious. Furthermore, INA is a useful marker in the differential diagnosis of OMT because its expression in these tumors is weak, if at all. Our data also provide a note of caution regarding the use of INA IHC as a replacement for classic molecular-genetic analysis; it has limited diagnostic specificity because it can also be found in cases of isolated/partial deletions of 19q or 1p or cases without deletion. In addition, it can be heterogeneously expressed even in tumors with 1p/19q codeletion. Therefore, INA staining cannot replace the molecular genetic analysis of the 1p/19q status. Finally, our data on INA expression might enhance understanding of the biology of 1p/ 19q codeleted tumors.
